Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cellbxhealth Plc ADR
(OP:
ANPCY
)
0.0670
UNCHANGED
Last Price
Updated: 2:45 PM EST, Dec 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cellbxhealth Plc ADR
< Previous
1
2
3
4
5
6
Next >
Angle PLC Announces Harvesting CTCs from Brain Metastasis Patients
July 09, 2021
PARSORTIX USED TO SUCCESSFULLY HARVEST CANCER CELLS FOR ANALYSIS FROM THE BLOOD OF PATIENTS WITH BRAIN METASTASIS Parsortix successful in overcoming challenges associated with isolating CTCs from brain...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Director/PDMR Shareholding
July 07, 2021
ANGLE plc Director/PDMR Shareholding Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / July 7, 2021 / ANGLE plc ('ANGLE' or the 'Company') (AIM:AGL) (OTCQX:ANPCY), a...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC announces Issue of Equity
July 02, 2021
Exercise of options and total voting rights GUILDFORD, UK / ACCESSWIRE / July 2, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Result of AGM
June 30, 2021
ANGLE plc ('the Company') Result of 2021 Annual General Meeting GUILDFORD, SURREY / ACCESSWIRE / June 30, 2021 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Annual General Meeting update
June 18, 2021
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, confirms that its Annual General Meeting (AGM) will be held as a closed meeting...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces ctDNA and CTCs have differences in EGFR mutations
June 18, 2021
- DIFFERENCES FOUND IN EGFR MUTATIONS BETWEEN ctDNA AND CTCs IN MATCHED LIQUID BIOPSIES FROM NON-SMALL LUNG CANCER PATIENTS - Study supports analysis of CTCs, together with ctDNA, from serial liquid...
From
ANGLE plc
Via
AccessWire
Topics
Death
Intellectual Property
Angle PLC Announces Update on Submission for FDA Clearance
June 04, 2021
UPDATE ON SUBMISSION FOR FDA CLEARANCE OF THE PARSORTIX SYSTEM Response to Additional Information Request made to FDA as planned GUILDFORD, UK / ACCESSWIRE / June 4, 2021 / ANGLE plc...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Potential to Prevent Breast Cancer Relapse
June 01, 2021
BREAKTHROUGH RESEARCH SUPPORTS POTENTIAL USE OF PARSORTIX IN PREVENTION OF RELAPSE OF BREAST CANCER PATIENTS IN REMISSION Parsortix system successfully used to harvest cancer cells "hibernating" in the...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Parsortix Demonstrates Oesophageal Cancer Utility
May 20, 2021
- Parsortix system consistently harvests CTCs of high quality - Research paves the way for downstream molecular analysis to enable targeted treatment in this hard-to-treat cancer GUILDFORD, UK /...
From
ANGLE plc
Via
AccessWire
Topics
Death
Intellectual Property
Angle PLC Announces Exercise of options and total voting rights
May 19, 2021
GUILDFORD, SURREY / ACCESSWIRE / May 19, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Parsortix study uncovers targets in TNBC patients
May 11, 2021
- Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets - Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Exercise of Options and Total Voting Rights
April 30, 2021
SURREY, UK / ACCESSWIRE / April 30, 2021 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Preliminary Results
April 29, 2021
ANGLE plc ("ANGLE" or "the Company") Preliminary Results for the year ended 31 December 2020 FDA SUBSTANTIVE REVIEW PROGRESSING LAUNCH OF CLINICAL LABORATORY SERVICES FIRST LARGE-SCALE CONTRACT WITH...
From
ANGLE plc
Via
AccessWire
Angle PLC- Ovarian Cancer Study Patient Enrolment Completed
April 26, 2021
PATIENT ENROLMENT COMPLETED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY Headline results from the Study expected in Q4 2021 Study designed to support launch of an ovarian cancer test from ANGLE's...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces First Large-Scale Pharma Services Contract Secured
April 16, 2021
- Contract Worth Up to US$1.2 Million With Potential for Further Contracts From the Same Customer - Parsortix System Being Utilised in Cancer Drug Trials for Liquid Biopsy Longitudinal Monitoring Which...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Angle PLC Announces Notice of Preliminary Results and Webcast
April 15, 2021
GUILDFORD, SURREY / ACCESSWIRE / April 15, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2020...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
ANGLE's Parsortix system showcased at AACR 2021
April 12, 2021
ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE Publication of study results demonstrating the capabilities of two new assays in clinical samples at AACR 2021...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.